CLINICAL_TRIALS
trial_result
· 2016-09-16
Clinical Trial Update: Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection [Phase 3]
Summary
Phase 3 trial update of Sofosbuvir/Velpatasvir fixed-dose combination for 12 weeks in adults with chronic hepatitis C infection.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2016-09-16